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Abstract
Cystatin C (CysC) expression in the brain is elevated in human patients with epilepsy, in animal models of
neurodegenerative conditions, and in response to injury, but whether up-regulated CysC expression is a manifestation
of neurodegeneration or a cellular repair response is not understood. This study demonstrates that human CysC is
neuroprotective in cultures exposed to cytotoxic challenges, including nutritional-deprivation, colchicine, staurosporine,
and oxidative stress. While CysC is a cysteine protease inhibitor, cathepsin B inhibition was not required for the
neuroprotective action of CysC. Cells responded to CysC by inducing fully functional autophagy via the mTOR pathway,
leading to enhanced proteolytic clearance of autophagy substrates by lysosomes. Neuroprotective effects of CysC were
prevented by inhibiting autophagy with beclin 1 siRNA or 3-methyladenine. Our findings show that CysC plays a protective
role under conditions of neuronal challenge by inducing autophagy via mTOR inhibition and are consistent with CysC being
neuroprotective in neurodegenerative diseases. Thus, modulation of CysC expression has therapeutic implications for
stroke, Alzheimer’s disease, and other neurodegenerative disorders.
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Introduction
CysC [1] is considered an important endogenous inhibitor of
cysteine protease activity because of its potent in vitro inhibition of
cathepsins B, H, K, L and S and its presence in all mammalian
body fluids and tissues (for review [2]). It has a broad spectrum of
biological roles in numerous cellular systems, with growth-
promoting activity, inflammation down-regulating function, and
anti-viral and anti-bacterial properties (for review [3]). It is
involved in numerous and varied processes such as cancer, renal
diseases, diabetes, epilepsy and neurodegenerative diseases such as
Alzheimer’s disease (AD). Its function in the brain is unclear but it
has been implicated in both the processes of neuronal degener-
ation and nervous system repair. Enhanced CysC expression
occurs in human patients with epilepsy, in animal models of
neurodegenerative conditions, and in response to injury, including
facial nerve axotomy, noxious input to the sensory spinal cord,
perforant path transections, hypophysectomy, transient forebrain
ischemia, and induction of epilepsy (for review [3]). It has been
suggested that this upregulation of CysC expression in response to
injury represents an intrinsic neuroprotective mechanism that may
counteract progression of the disease. In vitro studies using various
cell types exposed to a variety of toxic stimuli have reached
conflicting conclusions as to whether CysC is protective or toxic to
the cells (for review [3]).
The primary structure of CysC is indicative of a secreted protein
and accordingly, it has been demonstrated that most of the CysC is
targeted extracellularly via the secretory pathway and is taken up
by cells (for review [3]). Therefore, we have studied the effect of
exogenously applied human CysC on cells of neuronal origin
under neurotoxic stimuli, and show here that CysC protects
neuronal cells from death in a concentration dependent manner.
Moreover, primary cortical neurons isolated from brains of CysC
overexpressing transgenic mice [4] are more protected from death,
and cells isolated from CysC knockout mice [5] are more sensitive
to in vitro toxicity compared to cells isolated from brains of wild
type mice. Our results show that the mechanism of protection does
not involve inhibition of cysteine proteases such as cathepsin B.
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9819Using multiple methods, we demonstrate that CysC induces
autophagy in cells under basal conditions, and enhances the
autophagic activation in cells exposed to nutritional deprivation
and oxidative stress.
Autophagy usually occurs in normal cells to maintain cellular
turnover, and is greatly increased in cells under pathological
conditions that cause cell dysfunction such as trophic stress,
nutritional deprivation, hypoxia, and ischemia [6]. Macroauto-
phagy (hereafter referred to as autophagy) is the most abundant
type of autophagy that mediates sequestration and turnover of
organelles and cytoplasm. Its activation reduces the size of cells
and thereby decreases their metabolic burden, while generating
new substrates for energy and cellular remodeling [7,8]. During
autophagy a region of cytoplasm and organelles is sequestered by a
membrane that is created mainly from endoplasmic reticulum
under the direction of multiple proteins, including the microtu-
bule-associated protein MAP LC3-II, leading to the formation of a
double-membrane-limited autophagic vacuole (AV) or autophago-
some [9–11]. Autophagosomes mature to single membrane
autophagolysosomes [12–14] and become autolysosomes by fusing
with lysosomes [13]. Fusion of endosomes with autophagosomes
generates amphisomes, which are subsequently cleared by
lysosomes [15,16]. The term AVs is used to refer to any of these
compartments of the autophagic pathway, except lysosomes.
Autophagy induction may protect cells from apoptosis by
eliminating damaged mitochondria and other organelles that have
the potential to trigger apoptosis [17–20]. However, sustained
over-activity or dysfunction of the autophagic pathway in
pathologic states may mediate a caspase-independent form of cell
death that shares certain features with apoptosis [21–25].
The data presented here show that CysC induces autophagy in
neuronal cells in culture under basal conditions. Cells respond to
nutrition deprivation and to oxidative stress by inducing
autophagy as a protective mechanism although the level of
induction is not sufficient to maintain the survival of the cells. We
show here, however, that under stress conditions, increased CysC
levels hyper activate autophagy by further suppressing mTOR
activity. CysC-induced autophagy results in enhanced degradation
of long-lived proteins, which is directly related to neuroprotection.
This is the first demonstration, to our knowledge, that CysC
activates autophagy as a mechanism of cellular protection.
Results
Neuroprotection by CysC
We studied the role of CysC in the response to nutritional
deprivation in mouse neuroblastoma N2a cells incubated for 48
hours in serum-free medium in the absence or presence of
different concentrations of human CysC. The CysC concentra-
tions used in this study are within the range of physiological
concentrations of the protein in humans (less than 0.075 mMi n
serum and 0.135–0.693 mM in the CSF in subjects without
apparent disorders) [26].
Phase microscopy showed that serum-deprivation causes N2a
cell-death and that the addition of CysC to the culture medium
protects the cells in a concentration-dependent manner (Fig. 1A).
QuantificationoftheeffectofCysConcell-deathinducedbyserum-
deprivationwasperformedbycounting Hoechst nuclearstained live
cells (Fig. 1B). These data confirmed the visual observations and
showed that the effect of CysC on serum-deprived neuronal cells is
concentrationdependent,asconcentrationsof0.15 to0.4 mMC y s C
yielded dose-dependent increases in the survival of serum-deprived
neuronal cells and CysC concentration of 0.8 mM had a lesser
protective effect than 0.4 mM (Fig. 1B).
CysC also protected rat primary cortical neurons from either
spontaneous death induced by culturing procedures (Fig. 1C) or
more markedly from B27-supplement deprivation (Fig. 1D). The
cell survival quantification MTS assay was used to quantify
survival of rat primary cortical neuronal cultures incubated for 24
hours in B27-supplemented or B27-free neurobasal medium and
different concentrations of CysC. The same results were obtained
by quantification of survival using the Hoechst nuclear staining
assay (data not shown).
Moreover, overexpression of human CysC in primary cortical
neurons increased their resistance to toxicity induced by either
culturing or by deprivation of B27-supplement. Mouse primary
cortical neurons were cultured in neurobasal medium in either the
presence or absence of B27-supplement and cell survival was
quantified by the MTS assay. Cortical neurons isolated from
brains of CysC knockout mice were more sensitive to both in vitro
culturing and B27-deprivation-induced toxicity compared to cells
isolated from brains of wild type mice (Fig. 1E). Primary neurons
extracted from brains of homozygous transgenic mice overex-
pressing human CysC showed higher survival levels compared to
cells isolated from wild type mice (Fig. 1E). These data show that
enhanced CysC expression in neuronal cells can protect them
from toxicity-induced death.
B27-supplement contains compounds with antioxidant activities
[27], suggesting that CysC protects neuronal cells against oxidative
stress. This protective effect of CysC from oxidative stress was
confirmed in rat primary cortical neurons exposed to 10 mmH 2O2
(Fig. 2A).
CysC also protected rat primary cortical neurons from the
neurotoxic effects of a variety of other insults, including the
microtubule-depolymerizing agent colchicine (0.5 mM) (Fig. 2B),
and the apoptotic agent staurosporine (100 nM) (Fig. 2C).
Neuroprotection by CysC against serum-deprivation
does not involve cathepsin B inhibition
In order to test the possibility that the mechanism of protection by
CysC involves inhibition of cathepsin B, cathepsin B expression and
specific activity were measured in neuroblastoma cells under serum-
deprivationconditionsinthepresenceorabsenceofCysC.Cathepsin
B levels were quantified by Western blot analysis and normalized to
b-tubulin levels for each condition. Cathepsin B protein levels or
specificactivitydidnotdifferbetweencellsinthepresenceorabsence
of CysC (data not shown). We then compared the protective effect of
human urinary CysC, used in all the experiments described here,
with that of two other forms of the protein. The CysC isolated from
humanurineistruncatedattheN-terminusby10aminoacids,which
has been previously shown to diminish the cathepsin inhibitory
activity of the protein [28]. This truncated form was compared to a
recombinant fulllength human CysC and to a mutated recombinant
fulllength CysC inwhichmostofthe residues intheinhibitory active
site have been replaced by glycine residues, retaining its overall 3-D
structure. Compared to full length wild-type CysC, this Gly-
substituted variant has negligible inhibitory activity toward the
mammalian cysteine peptidases, cathepsins B, H, K, L, and S [29].
Measurements of cathepsin B specific activity in vitro confirmed that
the Gly-mutated CysC is unable to inhibit cathepsin B, and that the
N-terminally truncated human urinary CysC has lowered cathepsin
B inhibitory activity compared to full length human CysC (Fig. 3A).
Wethencomparedtherelativeprotectiveeffectsofthethreeformsof
CysC on mouse cortical primary neurons incubated in B27-
containing or B27-free neurobasal media (Fig. 3B). We used cells
derived from CysC knockout embryos [5] in order to specifically
study the effect of the three different forms of CysC in the absence of
full length endogenous CysC. Despite having markedly different
Cystatin C Induces Autophagy
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protected cultured cortical neurons from death induced by B27-
supplement deprivation (Fig. 3B). These data preclude cathepsin B
inhibition as the mechanism of protection by CysC under the
conditions tested here.
CysC does not protect neuronal cells from toxicity when
autophagy is blocked
Cells respond to nutritional withdrawal by inducing autophagy
that is crucial for cell adaptation and survival under extreme
conditions. This process allows the degradation of intracellular
macromolecules and provides the energy required for minimal cell
functioning when nutrients are scarce (for review [30]). We tested
whether or not the protective effect of CysC is preserved under
conditions in which autophagy is inhibited. CysC did not protect
N2a cells from the toxicity of the autophagy inhibitor, 3-
methyladenine (3MA) [31], under conditions of serum-deprivation
(Fig. 4A). To further advance our understanding of the role of
autophagy in the response of cells to CysC treatment, we studied
the consequences of autophagy disruption by treating N2a cell
Figure 1. In vitro neuroprotection by either extracellular or endogenouse human CysC. A. Light microscopy pictures of N2a cells
incubated for 48 hours in medium containing serum or in serum-free medium in the absence or presence of different concentrations of CysC. Scale
bar represents 100 mm. B. Neuronal survival was measured by counting live cells, and expressed as percentage of neuronal survival in cultures
incubated in serum-containing medium. Data are the mean and SEM of 4 experiments. C. D. Primary rat cortical neurons were cultured in neurobasal
medium in the presence (C) or absence (D) of B27-supplement and different concentrations of human CysC for 24 hours. Cell survival analyzed by the
MTS assay is expressed as percentage of live cells in cultures incubated in B27-supplemented medium without CysC. Data are the mean and SEM of 3
experiments. F and P values determined by one way ANOVA for (C) were 85.09 and ,0.0001 and for (D) 34.00 and ,0.0001. E Primary cortical
neurons isolated from brains of CysC knockout (CysCko), transgenic mice overexpressing human CysC (CysCtg), or wild type (WT) mice were
incubated in B27-supplement containing or lacking media. Survival is expressed as percentage of live cells in wild type cultures incubated in B27-
supplemented medium. For groups incubated with B27 the F and P values determined by one way ANOVA were 20.60 and 0.0007 and for groups
incubated without B27 were 68.93 and ,0.0001.
doi:10.1371/journal.pone.0009819.g001
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targeting specifically beclin 1 mRNA. Beclin 1 is a coiled-coil,
myosin-like BCL2-interacting protein, a well characterized
autophagy activator [31]. The two siRNA efficiently reduced
levels of beclin 1 expression in N2a cells (Fig. 4B). No significant
difference was observed between N2a treated with beclin 1 siRNA
in the presence or absence of CysC (Fig. 4C). Thus, silencing of
beclin 1 expression, which inhibits the autophagic process [31],
eliminated the protective effect of CysC from serum deprivation-
induced death (Fig. 4C).
CysC induces autophagy
LC3 is a selective marker for AVs, which appears cytosolic in
normal conditions (LC3-I) and becomes punctate when it is
lipidated and cleaved to form LC3-II that is associated with
membranes of AVs [31]. In order to analyze the effect of CysC on
the levels of LC3-labeled vesicles in serum deprived cell cultures,
we measured LC3-II and LC3-I protein levels in N2a cells
incubated in serum-containing or serum-free media, supplemented
with various concentrations of CysC. Immunohistochemical
studies using an anti-LC3-II enriched LC3 antibody indicated
that addition of CysC induced a concentration-dependent increase
in the number of LC3-II labeled vesicles (Fig. 5A).
In support of these data, Western blot analysis showed that
CysC enhances the formation of LC3-II in serum-deprived
neuronal cells (Fig. 5B). N2a neuroblastoma cells were incubated
in serum-supplemented or serum-free media and the serum-free
medium contained increasing concentrations of CysC. Cell lysate
proteins were separated by gel-electrophoresis and blotted with
anti-LC3 antibodies (Fig. 5B). Quantification of the LC3-I (16
kDa) and LC3-II (14 kDa) bands showed that N2a cells respond to
serum deprivation by the formation of LC3-II, and that CysC
treatment is associated with increased conversion of LC3-I into
LC3-II (Fig. 5C). Addition of CysC to serum-containing medium
also induced conjugation of LC3 in N2a cells (Fig. 5D and E),
revealing that CysC affects basal autophagy under normal culture
Figure 2. Neuroprotection of primary rat cortical neurons from
a variety of insults. Primary rat cortical neurons were cultured in B27-
supplemented neurobasal medium in the presence of 10 mMH 2O2 (A),
0.5 mM colchicine (B), or 0.1 mM staurosporine (C) and different
concentrations of human CysC for 24 hours. Cell survival analyzed by
the MTS assay is expressed as percentage of live cells in cultures
incubated in B27-supplemented medium without CysC. Data are the
mean and SEM of 3 experiments. F and P values determined by one way
ANOVA for (A) were 7.45 and 0.01. Differences between CysC treated
and untreated samples were calculated by Student’s t-test for B and C.
doi:10.1371/journal.pone.0009819.g002
Figure 3. CysC forms lacking cathepsin B inhibitory activity are
protective against nutrition-deprivation-induced cell death. A.
In vitro analysis of cathepsin B specific activity measured in the presence
of 1.7 mM of three different forms of CysC: recombinant full length
human CysC; recombinant full length CysC mutated in the inhibitory
active site (mutated); and N-terminally truncated human urinary CysC
(truncated). Cathepsin B inhibitory activity was calculated as activity per
mg of total protein and normalized for cathepsin B protein level,
presented as fluorescent units (fU). Data are the mean and SEM of 3
experiments. F and P values determined by one way ANOVA were 147.6
and ,0.0001. B. Cortical primary neurons derived from embryos of
CysC knockout mice were incubated in neurobasal medium either
containing or lacking B27, in the presence of 0.8 mM of the three forms
of CysC. Cell survival analyzed by the MTS assay is expressed as
percentage of live cells in cultures incubated in supplemented media
without CysC. Data are the mean and SEM of 3 experiments. F and P
values determined by one way ANOVA were 9.39 and 0.005.
doi:10.1371/journal.pone.0009819.g003
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LC3-II in primary cortical neurons isolated from CysC knockout
mice in either the presence or absence of B27-supplement (Fig. 5F
and G).
In order to confirm our finding that CysC induces autophagy in
neuronal cells, electron microscopy studies were conducted on rat
primary cortical neurons in B27-free medium in the absence or
presence of CysC (Fig. 6A). Counting the total number of AVs per
cell, including autophagosomes and autophagolysosomes, con-
firmed that the removal of B27-supplement induced the
appearance of AVs in these cells, and CysC further enhanced
this process (Fig. 6B).
CysC increases the levels of proteolysis in lysosomes
partially due to autophagy in serum-deprived
neuroblastoma cells
An increase in the number of AVs in the cell may result from
either enhanced generation of the vesicles or blockage of their
fusion with lysosomes. While induction of autophagy and resultant
enhanced protein degradation would protect the cell from toxic
insults, accumulation of AVs without their efficient clearance
could contribute to cell death. In order to differentiate between the
two conditions, we analyzed total protein degradation in serum-
deprived neuronal cells. Quantification of the rate of total protein
degradation in N2a cells showed increased proteolysis in the
presence of CysC in a dose-dependent manner (Fig. 7A).
The increase in protein degradation observed upon treatment
with CysC was no longer observed if lysosomal degradation was
inhibited by treatment with NH4Cl and leupeptin, indicating that
CysC stimulated protein degradation in lysosomes (Fig. 7B).
Because different types of autophagy can contribute to protein
degradation in lysosomes, we estimated the relative contribution of
macroautophagy to the observed changes in lysosomal protein
degradation, by performing similar experiments in 3MA treated
cells. Macroautophagy degradation is calculated as the percentage
of lysosomal degradation (sensitive to NH4Cl and leupeptine) that
can be inhibited by treatment with 3MA. Analysis of the
contribution of macroautophagy to the lysosomal degradation
induced by serum deprivation in the presence or absence of CysC
showed that CysC caused a marked shift of the lysosomal
degradation towards macroautophagy (Fig. 7C). These studies
confirm that the increase in the number of AVs observed in CysC
treated N2a cells was the consequence of enhanced autophagic
activity. These data indicate that CysC enhances the flux through
fully functional autophagy, resulting in delivery of cytosolic cargo
to lysosomes where degradation occurs.
CysC induces autophagy via the mTOR pathway
In order to determine the autophagic signaling pathway
induced by CysC, the effect of CysC on the level of p70S6 kinase
phosphorylation (p-p70S6 kinase), a substrate protein in the
mTOR pathway [31], was analyzed. N2a cells were incubated in
either serum-containing or serum-free medium in the absence or
presence of CysC. Cell lysate proteins were separated by gel
electrophoresis, transferred onto a membrane, and blotted with
antibodies to either p70S6 kinase or p-p70S6 kinase (Fig. 8A).
Band intensities were measured and p-p70S6 kinase levels were
calculated relative to total p70S6 kinase values. While the level of
p70S6 kinase was not affected by either serum deprivation or
CysC (Fig 8A), the level of its phosphorylation was significantly
reduced by CysC exposure in serum-containing medium (Fig. 8B).
Serum-deprivation, as expected, markedly reduced p70S6 kinase
phosphorylation and, importantly, a further significant reduction
of p70S6 kinase phosphorylation was achieved by the addition of
CysC to the serum-free medium (Fig. 8B). The phosphorylation
state of p70S6 kinase is an established index of mTOR activity
[32,33], with dephosphorylation of p70S6 kinase indicating
inhibition of mTOR, a negative regulator of autophagy. These
data, therefore, indicate that CysC induces autophagy through
inhibition of the mTOR-signaling pathway.
Figure 4. CysC does not protect neuronal cells from toxicity
when autophagy is inhibited. A. N2a cells were incubated for 44
hours in serum-free medium with 3MA, an inhibitor of autophagy, in
the presence or absence of 0.4 mM CysC. Neuronal survival was
measured by counting live cells, and expressed as percentage of
neuronal survival in cultures incubated in serum-deprived medium.
Data are the mean and SEM of 4 experiments. There were no significant
differences between samples containing 3MA with or without CysC. B.
N2a cells were treated with two forms of beclin 1 siRNA (a and b).
Western blot analysis with anti-beclin 1 antibody shows inhibition of
beclin 1 expression in treated cells. C. Beclin 1 siRNA treatment of N2a
cells attenuates the protective effect of CysC from serum-deprivation
induced death. Cell survival was measured by the MTS assay. Data are
the mean and SEM of 3 experiments. No significant difference between
CysC treated and non- treated cells was observed.
doi:10.1371/journal.pone.0009819.g004
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The data presented here demonstrate a protective effect of
CysC on neuronal cells cultured under serum-deprivation
conditions. CysC also protects primary cortical neurons against
the toxicity induced by oxidative stress, the microtubule-
depolymerizing agent colchicine, and staurosporine, a potent wide
spectrum inhibitor of protein kinases [34]. The secreted protein
[3], exogenously applied to neuronal cells, protects neuronal cells
from death in a concentration dependent manner. While an
increase in protection was observed for all CysC concentrations
added to the culture medium of primary cortical neurons, a
Figure 5. CysC induces cleavage of LC3 and the generation of vesicles stained for LC3-II, associated with autophagic vesicles. A. N2a
neuroblastoma cells were incubated for 18 hours in serum containing or serum-free media containing the indicated concentrations of CysC. Cells
were stained with an anti-LC3 antibody enriched for LC3-II and visualized in a fluorescence microscope. Scale bar represents 10 mm. BE. N2a cells
were incubated in serum-supplemented or serum-free media containing different concentrations of CysC for 12 hours. Cell lysate proteins were
analyzed by Western blot using anti-LC3 antibodies. Representative images of Western blot analyses of cell lysate proteins in serum-free medium (B)
and in serum-supplemented medium (D) are shown. The intensity of the LC3-I and LC3-II bands was measured and results are expressed as the ratio
of LC3-II to total LC3 (LC3-I + LC3-II) values (C and E). Data are the mean and SEM of 4 experiments. F and P values determined by one way ANOVA for
(E) were 5.11 and 0.02 (F and G) Western blots with anti-LC3 antibodies of primary cortical neurons isolated from CysC knockout mice incubated for
12 hours in media containing (F) or lacking (G) B27-supplement in the presence of different concentrations of CysC.
doi:10.1371/journal.pone.0009819.g005
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for N2a cells. These data suggest a difference in sensitivity to CysC
and/or bioavailability due to variable uptake or delivery of CysC
by different neuronal cell types. Moreover, endogenous CysC
overexpression in primary cortical neurons isolated from brains of
CysC transgenic mice [4] also protected the cells from spontane-
ous death induced by culturing and from B27-supplement-
deprivation. Cells isolated from CysC knockout mice [5] were
more sensitive to in vitro toxicity compared to cells isolated from
brains of wild type mice.
Multiple in vivo and in vitro studies have previously demonstrated
the involvement of CysC in the response to a variety of
neurodegenerative insults, supporting either a protective or toxic
effect of enhanced levels of CysC. Given the diverse roles that
CysC plays, CysC could either contribute to a cell-death
mechanism that is activated, or be protective by preventing cell
death, promoting cell survival, or promoting mitogenic activity
resulting in neurogenesis. The mechanisms that were previously
proposed to explain CysC function either involve inhibition of
cysteine proteases such as cathepsin B or are independent of
cathepsin inhibition. The demonstration of in vitro inhibition of
cysteine proteases by CysC suggested that CysC is an endogenous
inhibitor of lysosomal proteinases (for review [2]). Cathepsins have
been linked with cell death mechanisms and enhanced expression
of several cathepsins have been documented in response to injuries
similar to those inducing CysC upregulation (for review [35]).
Furthermore, inhibitors of cathepsins B and L reduced neuronal
damage in the hippocampus after ischemia (for review [35]). Thus,
an increase in CysC expression might be a response to rescue
neurons by inhibiting the apoptosis-promoting actions of cathep-
sins. However, CysC has a role in neuronal proliferation,
differentiation, and possibly neuroregeneration, independent of
its effects on cathepsin activity [36–40].
Leukocyte elastase in catalytic amounts was observed to rapidly
cleave the Val-10-Gly-11 bond of the human CysC at neutral pH.
The resulting truncated CysC had size and amino acid
composition consistent with a CysC molecule devoid of the N-
terminal decapeptide with a decreased inhibition of human
cathepsins B and L by three orders of magnitude [28]. We have
used human CysC isolated from urine that is amino-terminally
decapeptide truncated [41] and observed a low effect of CysC on
the activity of cathepsin B. We have shown that the protective
effect of this form of CysC is similar to that of recombinant full
length human CysC and to a mutated recombinant full length
CysC that lacks inhibitory activity [29]. These data preclude
cathepsin B inhibition as the mechanism of protection by CysC.
We have used a range of assays in order to establish that CysC
enhances autophagy in neuronal cells under toxic conditions as a
protective mechanism. The combination of assays used showed
that the observed increases in numbers of autophagosomes after
exposure to CysC reflects induction of a fully functional autophagy
pathway that includes competent proteolytic clearance of
autophagy substrates by lysosomes. We first demonstrated that
CysC protects neuronal cells from a variety of toxic insults, except
for the toxicity induced by 3MA, an inhibitor of autophagy. We
also showed that inhibition of autophagy by siRNA silencing of
beclin 1 prevents CysC from protecting the cells against serum
deprivation-induced death. We then showed that CysC causes
redistribution of LC3 to vesicular profiles with increased levels of
immunoreactive LC3-II vesicles accompanied by increased
conversion of LC3-I to LC3-II, as identified by Western blotting.
This change is associated with increased appearance of AVs in the
cytoplasm of cells with otherwise normal ultrastructural morphol-
ogy coupled with evidence for reduced mTOR activity (p70S6
kinase dephosphorylation). These observations strongly point to
CysC-stimulated induction of autophagy in the absence of
evidence for cellular degenerative changes (for review [42]). A
final link of evidence indicating that increased autophagosome
formation reflects increased autophagic activity is the demonstra-
tion by metabolic labeling that the rate of long-lived proteins
breakdown was increased by CysC treatment under nutrition
deprivation conditions. All these data combined indicate enhanced
flux through a fully functional autophagy pathway, resulting in
delivery to lysosomes where degradation occurs.
Autophagy is generally a cell survival mechanism [43], although
sustained over-activity or dysfunction of the autophagic pathway
mediates a caspase-independent form of cell death that shares
certain features with apoptosis [31]. Autophagy appeared at an
early stage of apoptosis of CA1 pyramidal neurons of the gerbil
hippocampus after brief ischemia; however, and it was proposed
that it protected the cells from death [42,44]. Our data suggest
that the increase in CysC immunoreactivity in the hippocampus of
animals in response to injury (for review [3]) induces autophagy as
an intrinsic neuroprotective mechanism.
There are several indications that CysC plays a protective role
in AD, a neurodegenerative disorder characterized by deposition
of Ab in the brain. 1) Genetic data demonstrated linkage of the
CysC gene (CST3) with an increased risk of developing late-onset
AD (for review [3,45]). The polymorphism in CST3 results in
reduced CysC secretion [46–48], and decreased CysC plasma
levels [49,50]. Mutations in the presenilin 2 gene linked to familial
AD (PS2 M239I and T122R) alter CysC trafficking in mouse
Figure 6. CysC induces an increase in the number of autophagic vesicles (AVs) in neuronal cells. Electron micrographs of primary rat
cortical neurons (A) incubated for 12 hours in either B27-supplemented or deprived medium in the absence or presence of 0.75 mM CysC. The total
number of AVs per cell was counted for at least 20 cells/condition, and the average number of vesicles per cell is shown (B). Data are the mean and
SEM. Differences between CysC treated and untreated samples were calculated by Student’s t-test.
doi:10.1371/journal.pone.0009819.g006
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levels of CysC may represent the molecular factor responsible for
the increased risk of AD and/or increased susceptibility to insult.
2) Immunohistochemical analyses have shown intensely CysC
immunoreactive neurons and activated glia in the cerebral cortex
of some aged human cases and of all AD patients [52,53].
Neuronal staining of CysC in AD brains was primarily limited to
pyramidal neurons in cortical layers III and V, which are the
neurons most susceptible to cell death in AD [53,54]. 3)
Immunohistochemical studies revealed co-localization of CysC
with Ab amyloid deposits in brains of patients with AD, Down’s
syndrome, cerebral infarction [54–58] and non-demented aged
individuals [54]. 4) CysC binds Ab and inhibits Ab oligomeriza-
tion [59] and fibril formation in vitro [60] and in vivo [61,62].
However, deletion of CysC in knockout mice resulted in an
increase in cathepsin B activity and an enhanced Ab degradation
[63]. Unlike a complete deletion of CysC, reduced or enhanced
levels of CysC expression affect the aggregation of Ab, not Ab
levels [61,62]. Extensive research has shown that Ab has an
important role in the pathogenesis of neuronal dysfunction in AD
(for review [64]). Ab has been shown to induce protein oxidation
Figure 7. CysC enhances total lysosomal-dependent protein
degradation in serum-deprived neuronal cells. A. Effect of
increasing concentrations of CysC on total rates of protein degradation.
N2a cells were labeled for 2 days with [
3H]-leucine. After extensive
washing, cells were incubated in serum-containing or serum-free media.
Removal of serum maximally activates lysosomal degradation. The cells
maintained in serum-free media were supplemented or not with
increasing concentrations of CysC as labeled. The rate of total protein
degradation at the indicated times was calculated as the percentage of
total radiolabeled protein transformed into soluble amino acids. B.
Effect of inhibition of lysosomal proteolysis on the CysC-induced
increase in protein degradation. N2a cells were labeled as in A and then
maintained in serum-free media and supplemented or not with CysC.
Where indicated 20 mM NH4Cl and 100 mM leupeptin were added to
inhibit lysosomal proteolysis. Protein degradation was calculated as in
A. C. Effect of CysC on macroautophagy-dependent proteolysis. N2a
cells labeled as in A and maintained in serum-free media were
supplemented or not with CysC. Half of the cells were treated with
10 mM 3MA to inhibit macroautophagy. The percentage of lysosomal
degradation that results from autophagic degradation (3MA sensitive),
in the presence or absence of CysC was calculated. Values are mean and
SED of triplicate wells in 3–4 different experiments. One way ANOVA for
differences between CysC treated and untreated samples were
significant for *p=0.05; **p=0.001 and between control and ammo-
nium chloride treated samples were significant for
+p=0.01.
doi:10.1371/journal.pone.0009819.g007
Figure 8. CysC induces autophagy via the mTOR signaling
pathway in either serum-containing or serum-free medium. A.
N2a cells were incubated for 12 hrs in serum-containing or serum-free
medium in the presence or absence of CysC. Cell lysate proteins were
separated by gel electrophoresis and blotted with antibodies to P70S6
kinase, p-P70S6 kinase (Thr389), or b-tubulin. Representative images of
Western blot analysis are presented. B. The intensity of the bands was
measured, and p-P70S6 protein levels were calculated relative to total
P70S6 values showing a decrease in the level of P70S6 kinase
phosphorylation. Data are the mean and SEM of 6 experiments. For
serum containing groups the F and P values determined by one way
ANOVA were 9.07 and 0.006 and for serum deprived groups were 10.18
and 0.005.
doi:10.1371/journal.pone.0009819.g008
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play a central role as a mediator of free radical induced oxidative
stress and neurotoxicity in AD brain (for review [65]). We have
demonstrated that the addition of CysC together with preformed
oligomeric or fibrillar Ab to either cultured primary hippocampal
neurons or to N2a cells increased cell survival. While CysC inhibits
Ab aggregation, it does not dissolve preformed Ab fibrils or
oligomers [59,60]. Thus, CysC has a dual protective effect from
Ab toxicity. It inhibits Ab aggregation, in addition to the direct
neuroprotective effect that is independent of its anti-Ab amyloi-
dogenetic property.
Autophagy has been implicated in the neurodegeneration and
amyloidogenesis of AD [66,67]. Extensive autophagic pathology
observed in AD includes massive accumulation of AVs in affected
neuronsand dystrophicneuritesandmostlikelyarisesfromimpaired
clearance of AVs [68]. Ab is normally generated by autophagic
turnover of the amyloid precursor protein and subsequently cleared
withinthelysosomalsystembut buildsupinaccumulatedAVsinAD
brain [69–71]. Beclin 1 is reported to be decreased in AD, further
disruptingautophagyandpromotingAbgeneration[71].Adecrease
in CysC levels in AD patients may contribute to this pathology. Our
data show multiple possible neuropathological consequences of the
reduced levels of CysC in AD, including an increase in Ab
accumulation and amyloid deposition as well as a reduced ability to
protect from toxicity in the brain.
Accumulating data show that CysC functions via several
independent pathways in response to a variety of toxic insults.
The data presented here reveal a novel protective pathway that is
independent of protease inhibition and involves induction of
autophagy as a necessary aspect of the protective mechanism.
Therapeutic manipulation of CysC levels resulting in slightly
higher concentrations than physiological, either systemic or local,
could protect neuronal cells from cell death in neurodegenerative
disorders, such as Alzheimer’s disease.
Materials and Methods
Cell culture
N2a cells (ATCC, Manassas, VA) were grown in Dulbeco’s
Modified Eagle Medium (DMEM) (Gibco Life Technologies-
Invitrogen, Grand Island, NY) supplemented with 10% fetal
bovine serum (FBS) (Gemini Bio-products, West Sacramento, CA),
1% penicilin-streptomicin, and 1% glutamine. For serum-
deprivation studies cell cultures were washed twice with warm
PBS and once with warm serum-free medium and incubated in
either serum-supplemented or serum-free medium. Different
concentrations of human urinary CysC (Calbiochem- EMD
Bioscience, San Diego, CA) were added into the medium. The
autophagy inhibitor, 3-methyladenine (3MA) (10 mM; Sigma, St
Louis, MO), was added to serum-free medium in the presence or
absence of CysC.
Primary cultures of cortical neurons
Primary cultures of cortical neurons were established from
either prenatal E19 pups of pregnant Sprague-Dawley rats
(Charles River Labs), or from prenatal E16 pups of pregnant
mice. All procedures involving experiments vertebrate animals
received prior approval of the Nathan S. Kline Institute Animal
Care and Use Committee, in accord with the provisions of the
PHS ‘‘Guide for the Care and Use of Laboratory Animals’’ and
the ‘‘Principles for the Utilization and Care of Vertebrate
Animals’’. Brains were placed in cold Hybernate E/A medium
(BrainBits, Springfield, IL), and cortices containing the hippo-
campus were dissected out using a dissection microscope. Cortices
were minced and incubated in 20 u/ml papain solution
(Worthington) for 20 min at 37uC. The tissue was triturated in a
papain blocking solution (20% FBS from Hyclone, 0.2 mg/ml
DNase, and 0.1 M MgSO4 in neurobasal medium with supple-
ments). Cell suspension was filtered through a 0.4 mm filter unit
and centrifuged at 2006g for 3 min. The pellet containing the
dissociated neurons was resuspended in neurobasal medium with
supplements (2% B27, 100 U/ml penicillin, 100 mg/ml strepto-
mycin sulfate and 0.30% glutamine) and viable cells were counted
using a haemocytometer. Neurons were plated at a density of
2.5610
6 cells/cm
2 on 50 mg/ml poly-d-lysine coated coverslips
and incubated at 37uCi n5 %C O 2 atmosphere. Half of the culture
medium was replaced every 3 days. Neuronal cultures were
treated after 6–7 days in culture. For B27-supplement-deprivation
studies neuronal cultures were extensively washed in saline
solution I (8.1 g/l NaCl, 0.4 g/l KCl, 0.15 g/l Na2HPO4,
0.15 g/l KH2PO4, 4 g/l dextrose pH 7.2) and then incubated in
B27-supplemented or -deprived neurobasal medium in the
presence or absence of different concentrations of CysC. 10 mM
H2O2, 0.5 mM colchicine, or 0.1 mM staurosporine were added
into B27-supplemented neurobasal medium.
Beclin 1 silencing
N2a cells were treated with 10 nM of beclin 1 siRNA (Mm
214165 (a) or Mm 214172 (b); Qiagen, Valencia CA) and 20 nM
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) in 20%
Optimem (Gibco, Carlsbad, CA) and 80% complete medium
(DMEM, Gibco, Carlsbad, CA) supplemented with 1% Glutamine
(Gibco, Carlsbad, CA) and 10% fetal bovine serum (Cellgro,
Manassas, VA) using a reverse transfection method in 96 well plate
(200 ml final volume, 2500 cells per well) for 72 hours. Inhibition of
beclin 1 expression was verified by Western blot analysis with anti-
beclin 1 antibody (BD Transduction Bioscience, San Jose, CA).
N2a cells were then washed twice with PBS, once with serum-free
medium (DMEM (Gibco, Carlsbad, CA) supplemented with 1%
Glutamine (Gibco, Carlsbad, CA) and incubated in serum-free
medium with or without CysC (0.75 mM) for 48 hours. Mean and
standard error of the mean (SEM) were calculated for 3 separate
experiments.
Neuronal viability assay by Hoechst staining
Cell cultures were washed with PBS, incubated with 0.4 mg/ml
Hoechst 33258 (Invitrogen, Carlsbad, CA) solution for 5 min at
room temperature, washed, fixed with 4% paraformaldehyde for
20 min at room temperature, and mounted using aqueous
mounting medium with anti-fading agents (Biomeda, Foster City,
CA). Live cells from entire wells were counted using the MCID’s
automatic target detection program in an Olympus BX60 system.
Neuronal survival was expressed as percentage of neuronal
survival in cultures incubated in serum-containing medium. Mean
and standard error of the mean (SEM) were calculated for 4
separate experiments.
CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (MTS)
20 ml of the CellTiter 96 Aqueous One Solution Reagent
(Promega, Madison, WI) were added into each well of the 96 wells
plate containing cells in 100 ml culture medium, incubated with
the reagent for 3 hours at 37uCi n5 %C O 2 and absorbance at
490 nm was recorded. As a negative control cell-free medium was
included. Neuronal survival was expressed as percentage of
neuronal survival in serum-free medium cultures. Mean and
SEM were calculated for 3 separate experiments.
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Intact, full-length, CysC and an anti-proteolytically defect
CysC-variant with the residues 8, 9, 10 and 106 in its inhibitory
center replaced by glycine-residues were isolated from periplasmic
extracts of bacterial clones containing the appropriate expression
plasmids as previously described [29]. CysC, devoid of the 10
amino-terminal residues of protein, resulting in reduced anti-
proteolytic activity, was isolated from native human urine as
earlier described [72].
Immunohistochemical staining for LC3-II
Cell cultures were washed with PBS and fixed in 4%
paraformaldehyde in PBS for 20 min at room temperature. After
PBS washing, cells were blocked for 1 hour at room temperature
with 2% BSA, 2% FBS in PBS, and incubated with anti-LC3-II
antibody (1:500) in blocking solution containing 0.1% saponin
overnight at 4uC. Cells were incubated in Alexa Fluor 488 goat
anti-rabbit IgG (1:100, Invitrogen, Carlsbad, CA) for 2 hours at
room temperature, mounted with aqueous gel mount (Biomeda,
Foster City, CA), and visualized by a fluorescence microscope
(Olympus BX60).
Western blot analysis
Cells were harvested in lysis buffer (1% Nonidet P-40, 1% Na
deoxycolate, 0.1% SDS, 150 mM NaCl, 10 mM Na phosphate
pH 7.2) containing protease inhibitors (5 mg/ml Leupeptin-Anti-
pain-Pepstatin A mix, 1 mM PMSF) and 1% phosphatase
inhibitors for phosphorylated proteins and centrifuged at
10,0006g for 10 min. Protein concentration was determined by
BCA Protein Assay Kit (Pierce, Rockford, IL). Equal amounts (10–
30 mg) of total proteins were boiled in sample buffer (1% SDS, 3%
glycerol, 1.5% b-mercaptoethanol and 20 mM Tris-HCl, pH 6.8)
and separated by 4–12% tris-glycine gel electrophoresis. The
proteins were electrophoretically transferred onto a 0.2 mm
nitrocellulose membranes (BioRad, Hercules, CA) in 2.5 mM
Tris/19.2 mM Glycine/20% methanol transfer buffer. The
membranes were blocked in 5% milk (BioRad, Hercules, CA) or
5% BSA in 10 mM Tris, 150 mM sodium chloride, pH 7.5, 0.1%
Tween-20 (TBST), incubated with primary antibody for 2 hours
at room temperature or overnight at 4uC, and with secondary
antibody for 1–2 hours at room temperature, and in chemilumi-
niscent fluid (Millipore, Billerica, MA) for 60 seconds prior to
exposure. The membranes were imaged using a Fuji LAS-3000 gel
documentation unit for 10–60 seconds. Quantification was
performed by digital image using the native Fuji software,
ImageGauge. For LC3, 20 mg was loaded per lane onto 16%
tris-gylcine gels, and following electrophoresis and transfer,
membranes were incubated for 4 hours with the primary antibody
in 3% milk with TBST, 1 hour in secondary antibody, and in
chemiluminescent fluid (Millipore, Billerica, MA) [68,70], visual-
ized on Reflection Autoradiography film and bands intensity was
quantified using the Quantity One program. Mean and SEM were
calculated for 4 separate experiments.
Antibodies used: anti-rat LC3 + anti-human LC3 (1:1,000), anti-
P70S6 kinase (1:1,000; Cell Signaling, Danvers, MA), anti-p-
P70S6 kinase (1:1,000; Cell Signaling, Danvers, MA), beclin 1
(1:1,500; BD Transduction Bioscience, San Jose, CA), b-tubulin
(Pierce, Rockford, IL), b-actin (Abcam, Cambridge, MA).
Electron Microscopy
Cells incubated on coverslips were washed thrice in either
serum-free DMEM or supplement-free Neurobasal media, and
fixed in 4% paraformaldehyde and 1% glutaraldehyde in 0.1 mol/
L sodium cacodylate buffer (pH 7.2) overnight at room temper-
ature. Following fixation, coverslips containing cells were washed
in cacodylate buffer, postfixed in 1% osmium tetroxide, and
progressively dehydrated through graded series of ethanol. The
cells were then in situ embedded following infiltration in
embedding medium (Epon 812 Mixture; Electronmicroscopy
Sciences) by inverting 2/3 filled beem (size # 3) capsules over
the cells. Thin sections were cut, mounted onto copper grids,
contrasted with Uranyl acetate and Reynold’s lead citrate, and
examined using Philips CM 10 electron microscope. Images were
captured on a digital camera (Hamamatsu; model C4742-95)
using Advantage CCD Camera System software (Advanced
Microscopy Techniques Corporation). The number of AVs per
cell was counted for at least 20 cells per condition, in images taken
at magnitude of67,900 (64 mm
2). Mean and SEM results of three
independent experiments are presented. Types of AVs were
identified by visual inspection of the micrographs using previously
established criteria [13,66]. Briefly, AVs (vesicles .0.5 mm) were
classified as autophagosomes when they met two or more of the
following criteria: double membranes (complete or at least
partially visible), absence of ribosomes attached to the cytosolic
side of the membrane, luminal density similar to cytosol, and
identifiable organelles or regions of organelles in their lumen.
Vesicles of similar size but with a single membrane (or less than
40% of the membrane visible as double), luminal density lower
than the surrounding cytosol, multiple single membrane-limited
vesicles containing light or dense amorphous material were
classified as autophagolysosomes.
Cathepsins B activity assay
Cells in 100 mm plates were scraped in 5 ml of PBS,
centrifuged, washed with PBS, and homogenized at pH 7.0.
30% of the sample was used for Western blot analysis.
Homogenates were acidified at pH 5.5 and Cathepsin B was
assayed by measuring the release of 7-amino-4-methylcoumarin
(amc) from Z-Arg-Arg-amc as described [73]. Assays were
performed in white micro plates in a volume of 200 ml mixture
(1–5 ml of enzyme or lysate; 50 ml of 0.1% Brij-35; and 145 mlo f
0.1 M sodium phosphate buffer pH 6.0 containing 2 mM EDTA
and DTT; 1 mM PMSF, 5 mM pepstatin A and 5 mM Z-Arg-
Arg-amc). Fluorescence of amc released after two hours was read
in a Wallac Victor-2 spectrofluorimetric plate reader with a filter
set optimized for detection of 4-methyl-7-aminocoumarin (-amc)
standard solution with excitation at 365 nm and emission at
440 nm. Enzyme activity was expressed as the amount of amc
released per hour per mg protein.
Intracellular Protein Degradation Measurements
Total protein degradation in cultured cells was measured by
pulse-chase experiments [30]. Confluent cells were labeled with
[
3H]-leucine (2 mCi/ml) for 48 hours at 37uC in order to
preferentially label long-lived proteins. Following labeling, cells
were extensively washed and maintained in complete medium
(DMEM + 10% FBS), under which conditions autophagy is
suppressed, or in serum-deprived medium, where autophagy is
induced. Under both conditions, after washing the cells, the
medium was supplemented with unlabeled 2.8 mM leucine to
prevent [
3H]-leucine reutilization. Aliquots of the medium taken at
different time-points were precipitated with 10% TCA, filtered
using a 0.22 mm pore membrane and radioactivity in the flow-
through and in the filters was measured. Proteolysis was expressed
as the percentage of the initial acid-precipitable radioactivity
(protein) transformed to acid-soluble radioactivity (amino acids
and small peptides) over time. Where indicated, either 20 mM
Cystatin C Induces Autophagy
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immediately after the labeling period and maintained at that
concentration throughout the chase.
Statistical analyses
The statistical significance was determined by one-way analysis
of variance (ANOVA) followed by the Bonferroni post hoc test to
determine significance of differences between multiple test groups.
Student’s T-test was used to determine significance when only two
groups were compared. Differences were significant for *p=0.05;
**p=0.01; and ***p=0.001.
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